Systematic modeling of tumor-microenvironment–mediated NK cell dysfunction in pancreatic cancer to identify KLRB1 as a target for cell engineering.

M Mingming Lu J Jialu Kang (The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China) B Bo Liu J Jing Lu X Xin Yan (Department of Chemistry) Y Yong Zhang Y Yidi Wang Y Yize Jiang (The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China) S Sha Peng (The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China) R Ruoxi Zhong (The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China) M Minyu Kong (The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China) C Chunzhe Zhang (The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China) Y Yifei Ma

Abstract

e14541 Background: Adoptively transferred natural killer (NK) cells fail in pancreatic ductal adenocarcinoma (PDAC) due to rapid functional suppression within the immunosuppressive tumor microenvironment (TME). A precise understanding of the dominant inhibitory mechanisms, especially those exerted by cancer-associated fibroblasts (CAFs) and soluble tumor-derived factors, is lacking. We hypothesized that a systematic, multi-model dissection of PDAC-mediated suppression could reveal conserved, targetable pathways for engineering resistant NK cells. Methods: To model the PDAC TME, we used two complementary in vitro suppression systems—co-culture of expanded human peripheral blood NK cells with patient-derived CAFs (cell-contact inhibition) and culture in conditioned medium from patient-derived PDAC organoids (soluble-factor inhibition)—and performed scRNA-seq to identify the most consistently upregulated inhibitory receptor, knocked it out in primary human NK cells using CRISPR–Cas9, and compared functional recovery of WT versus KO NK cells in both in vitro models and in an NSG mouse co-engrafted with human PDAC cells and CAFs. Results: scRNA-seq of NK cells exposed to either CAF co-culture or PDAC organoid CM revealed a shared and dominant upregulation of the inhibitory receptor KLRB1 (encoding CD161). CRISPR-mediated KLRB1-KO did not impair NK cell development or basal cytotoxicity. Critically, under both suppression models, KLRB1-KO NK cells maintained significantly higher levels of degranulation (CD107a+) and IFN-γ production compared to WT NK cells. Transcriptomically, KO cells preserved effector gene programs and exhibited attenuated induction of exhaustion signatures. In the in vivo co-engraftment model, adoptively transferred KLRB1-KO NK cells mediated superior tumor control. Single-cell analysis of NK cells recovered from tumors confirmed that KO cells maintained a higher frequency of a transcriptionally active effector cluster, whereas WT NK cells were predominantly driven into dysfunctional states. Conclusions: By systematically modeling both contact-dependent and soluble-mediated immunosuppression, we identify KLRB1 as a central, conserved "molecular brake" induced in NK cells by the PDAC TME. Its deletion generates "TME-resilient" NK cells with preserved effector function in situ. This work validates a discovery pipeline using complementary TME models and establishes KLRB1-KO as a promising strategy to engineer next-generation allogeneic NK cell products for overcoming microenvironmental suppression in solid tumors.

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (13)

M

Mingming Lu

J

Jialu Kang

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

B

Bo Liu

J

Jing Lu

X

Xin Yan

Department of Chemistry

Y

Yong Zhang

Y

Yidi Wang

Y

Yize Jiang

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

S

Sha Peng

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

R

Ruoxi Zhong

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

M

Minyu Kong

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

C

Chunzhe Zhang

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

Y

Yifei Ma